Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Replimune Group, Inc.NASDAQ: REPL

Other Income / Expenses · Q3 FY2026 · quarter ended Dec 2025

Other income / expenses growth accelerates

Q3 FY2026 other income / expenses of $627K rose 146.9% year over year, ahead of the -20.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 47.4% from the prior quarter. Over 3 fiscal years it compounded at +276.2% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +146.9% holds above the trailing-twelve-month pace of -20.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$627K-47.4% QoQ
Last fiscal yearMar 2025
$14.8M-23.7% YoY
LTMDec 2025
$10.64M-20.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+146.9%——
1 year-23.7%——
3-year CAGR+276.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
14.8M USD
Year-over-year change
-23.7%

Other Income / Expenses vs competitors

How REPL compares with its peers on the latest reported figures

  • REPL's LTM Dec 2025 other income / expenses of $10.64M is the 4th highest of the 11 companies compared; the peer median is $5.14M.
  • Its year-over-year change of -20.2% is the 6th highest of 10, against a peer median of -20.1%.
  • Over three fiscal years its annual growth of +276.2% compares with a peer median of +35.1%.
REPL Competitors Peer median
Other Income / Expenses for REPL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$54.3M +157.6%—43.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.51M +18.6%+121.9%196.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$18.56M -20.1%+84.3%2.6%
REPLReplimune Group, Inc.LTM Dec 2025$10.64M -20.2%+276.2%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$8.6M -33.8%+20.0%2.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$5.75M -2.2%+37.4%16.2%
ADAGAdagene Inc.LTM Jun 2024$4.52M —-7.1%554.5%
CGENCompugen Ltd.LTM Mar 2026$4.18M -19.6%+32.8%5.8%
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M -116.5%—4.7%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M -309.6%—175948.4%
IBRXImmunityBio, Inc.LTM Sep 2026-$835.68M -850.2%—457.7%
Peer median (excluding REPL) $5.14M-20.1%+35.1%30.0%

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue4.14M4.58M000
Gross Profit(4.14M)(4.58M)000
Gross Margin—————
Research & Development57.49M80.65M126.53M174.96M189.45M
Selling, General & Admin21.13M36.26M000
Operating Expenses78.62M116.91M177.08M234.77M261.63M
Depreciation & Amortization4.14M4.58M2.45M5.08M5.93M
EBITDA(76.48M)(114.41M)(171.72M)(227.77M)(253.92M)
EBITDA Margin—————
Operating Income(82.76M)(121.48M)(177.08M)(234.77M)(261.63M)
Operating Margin—————
Interest Income916K390K10.01M23.36M21.12M
Interest Expense3.06M2.22M4.16M6.66M7.89M
Other Income / Expenses(915K)278K3.08M19.39M14.8M
Income Before Tax(83.68M)(121.21M)(174M)(215.39M)(246.83M)
Pre-Tax Margin—————
Income Tax Expense(2.81M)(3.17M)288K408K468K
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Net Margin—————
EPS (Basic)(1.75)(2.26)(2.99)(3.24)(3.07)
EPS (Diluted)(1.75)(2.26)(2.99)(3.24)(3.07)
Weighted Avg Shares46.25M52.21M58.21M66.57M80.56M
Weighted Avg Shares (Diluted)46.25M52.21M58.21M66.57M80.56M

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.